Newsletters

[OncLive] The FDA has granted breakthrough therapy designation to enzomenib for the treatment of patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

[Bioengineer.org] Researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and the University of California San Francisco have received a five-year, $3.46 million grant from the National Cancer Institute to investigate why some older adults with AML respond to treatment while others do not.

[OGT] OGT announced the launch of the SureSeq myPanel™ Myeloid Fusion MRD Panel, the first-to-market dedicated fusion MRD next-generation sequencing (NGS) panel for AML.

[Nature Communications] Genetic targeting of NYN domain and retroviral integrase containing (NYNRIN) impairs leukemia stem cell (LSC)-like cell maintenance and in vivo leukemogenic capacity in MLL-AF9- and HOXA9/MEIS1-driven AML models, and compromises the in vivo pathogenicity of patient-derived LSC-like cells.

[Nature Immunology] Researchers identified a previously unrecognized hematopoietic site at the maternal–fetal interface in mice, termed MIXER (Maternally Interfaced eXtraEmbRyonic) tissue, which develops contemporaneously with the yolk sac and exhibits robust hematopoietic activity.

[Experimental Hematology] Scientists integrated insights from both developmental and engineered systems to outline shared principles of human HSC formation and highlight opportunities to refine in vitro strategies for producing fully functional HSCs.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators demonstrated that transient inhibition of Ataxia-Telangiectasia Mutated (ATM) kinase markedly enhanced KI efficiency in mouse HSCs genome-edited with Cas9/ribonucleoprotein and AAV donor DNA.

[Leukemia] The authors reported that a subset of human AML cell lines and primary samples are completely dependent on external serine, known as serine auxotrophy.

[Molecular Therapy] Scientists reported a scalable, ligand-free hematopoietic stem and progenitor cells (HSPCs)-tropic lipid nanoparticle enabling efficient mRNA delivery to human HSPCs in vivo without conditioning.

[Blood Advances] Investigators retrospectively reviewed the treatment courses of 34 patients with relapsed/refractory extranodal natural killer (NK)/T-cell lymphoma who underwent allogeneic HSC transplantation.

[International Immunopharmacology] Scientists generated both global and hematopoietic-specific Dock2 knockout mouse models. Results from routine blood analyses and flow cytometry consistently revealed pronounced anemic characteristics in Dock2-deficient mice.

[Nautilus Biotechnology, Inc. ] Nautilus Biotechnology, Inc. announced its participation in SEEDS (Sequence-to-disease: Environment-aware Ensembles of Disordered proteins at Scale), a four-year, multi-center research consortium. Nautilus expects to receive up to $6 million over the duration of the program to deploy its Voyager Platform to measure proteoforms, starting with Alzheimer’s disease and Ewing sarcoma.